Earlier today, Sony unveiled what the company has been teasing this past week showing off a couple trailers hinting at something related to PlayStation All-Stars: Battle Royale. It appears that the creators of the popular “Michael” trailer worked on making a very short film for the game.
The short film, titled “The All-Star” contains a battle scene between four iconic PlayStation characters. The video apparently contains hidden references to some secrets found in the game. The studio behind PlayStation All-Stars: Battle Royale did tease that there could be more hidden characters in the game.
PlayStation All-Stars: Battle Royale is set to release November 20th.
In other news, Eric Lempel, VP of Sony Network Entertainment revealed that an update will be coming to the PS3 next week with firmware 4.30, which will bring PlayStation Vita trophy integration to the home console. The trophy screen will get a slight modification adding a PS Vita tab which will also show its progress bar to next level up.
Lempel also revealed that the long-time running PS3 app, Life with PlayStation will be retiring after nearly six years of crunching numbers to find a cure for cancer, Parkinson’s and Alzheimer’s which was done by Stanford University’s Folding@home.
More than 15 million users have used the Life app on their PS3 resulting in more than 100 million computation hours for the Folding@home program. According to Stanford University research lead, Vijay Pande revealed that as a direct result of Life on the PS3, the research facility is very close to pushing a viable drug that combats Alzheimer’s disease.
Pande’s full statement:
The PS3 system was a game changer for Folding@home, as it opened the door for new methods and new processors, eventually also leading to the use of GPUs. We have had numerous successes in recent years. Specifically, in a paper just published in the Journal of Medicinal Chemistry, we report on tests of predictions from earlier Folding@home simulations, and how these predictions have led to a new strategy to fight Alzheimer’s disease. The next steps, now underway at Stanford, are to take this lead compound and help push it towards a viable drug. It’s too early to report on our preliminary results there, but I’m very excited that the directions set out in this paper do appear to be bearing fruit in terms of a viable drug (not just a drug candidate).